About
Titles
Professor Adjunct
Biography
Jean Bosco Ouedraogo is a MD, parasitologist and Researcher with a distinguished scientific career with major contributions to science in Burkina Faso. He is also a Professor of parasitology at the universities of Ouagadougou and Bobo-Dioulasso. Since 1983, He have conducted a series of studies on the resistance to different antimalarial drugs using in vivo, in vitro and molecular techniques. Recently he participated and played an important role in the RTS,S malaria vaccine trial in Burkina. He is currently investigating the potential benefit of adding azithromycin to the antimalarials used for SMC and a comparative study of SMC and seasonal vaccination with RTSS. He is also PI of many ongoing clinical trials and vaccine trials in the region of Bobo-Dioulasso, Burkina Faso.
His scientific contributions have been presented in over 185 peer reviewed publications.
In addition to the scientific activities he has had substantial administrative responsibilities acting as director of Institut de Recherche en Sciences de la Santé (IRSS) in Bobo-Dioulasso from 1999-2015 and Director General of the Centre Muraz from 2009 -2013.
He is currently:
- Head of Malaria & Neglected Tropical Diseases Unit, IRSS
- Director General of INSTech, Bobo-Dioulasso
- Executive secretary of WAHRNET (West African Health Research Network)
Appointments
Epidemiology of Microbial Diseases
Professor AdjunctPrimary
Other Departments & Organizations
- Epidemiology of Microbial Diseases
- Epidemiology of Microbial Diseases (EMD)
- Yale School of Public Health
- Yale School of Public Health - NEW
Research
Overview
Public Health Interests
Antimicrobial Resistance; Clinical Trials; Disease Transmission; Emerging Infectious Diseases; Epidemiology Methods; Ethics; Genetics, Genomics, Epigenetics; Health Economics; Health Policy; HIV/AIDS; Immunology; Infectious Diseases; Influenza; Malaria; Maternal & Child Health; Parasitology; Community Engagement; Vaccines; Viruses; Zoonotic Diseases; Vector Biology; Microbiome; Capacity Building; Neglected Tropical Diseases; Non-Communicable Diseases; Enteric Diseases; Implementation Science; Mosquito-borne Diseases; Randomized Trials; Trypanosomiasis; Vector-borne Diseases; Tick-borne Diseases; COVID-19
ORCID
0000-0003-0412-8733
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jean Bosco Ouedraogo's published research.
Publications Timeline
A big-picture view of Jean Bosco Ouedraogo's research output by year.
Sunil Parikh, MD, MPH
Amy Bei, PhD
Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS
Justin Goodwin
Martina Wade
Adam V Wisnewski, PhD, D(ABMLI)
243Publications
9,209Citations
Publications
2024
A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors
Ouattara S, Hien D, Nao E, Paré P, Guissou E, Cohuet A, Morlais I, Yerbanga R, Dabiré K, Ouédraogo J, Mouline K, Lefèvre T. A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors. Malaria Journal 2024, 23: 135. PMID: 38711028, PMCID: PMC11075210, DOI: 10.1186/s12936-024-04969-0.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsDirect membrane feeding assaysGametocyte densityHuman-to-mosquito transmissionDonor bloodLow gametocyte densitiesMembrane feeding assaysPlasmodium falciparum gametocytesTransmission-blocking interventionsWhole bloodInfection rateFalciparum gametocytesInfectious reservoirNaive serumAsymptomatic individualsMosquito infectionHuman donorsRemoval of plasmaEndemic countriesSerumPlasmodiumParasite isolatesInfectionBlood treatmentGametocytesPlasma volumeEx vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchConceptsResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapyThe public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research CouncilSafety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo M, Dicko A, Tinto H, Ouédraogo J, Hamaluba M, Olotu A, Beaumont E, Lopez F, Natama H, Weston S, Chemba M, Compaore Y, Issiaka D, Salou D, Some A, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood B, Ewer K, Bradley J, Kulkarni P, Shaligram U, Hill A, Group R, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko O, Kaya M, Maguiraga S, Sankare Y, Yalcouye H, Diarra S, Niambele S, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga R, Samtouma W, Sienou A, Kabre Z, Ouedraogo W, Yarbanga G, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni F, Sanre T, Ouattara S, Provstgaard-Morys S, Woods D, Snow R, Amek N, Ngetsa C, Ochola-Oyier L, Musyoki J, Munene M, Mumba N, Adetifa U, Muiruri C, Mwawaka J, Mwaganyuma M, Ndichu M, Weya J, Njogu K, Grant J, Webster J, Lakhkar A, Ido N, Traore O, Tahita M, Bonko M, Rouamba T, Ouedraogo D, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 2024, 403: 533-544. PMID: 38310910, DOI: 10.1016/s0140-6736(23)02511-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsClinical malaria episodesPhase 3 trialMalaria episodesMonths age groupAdverse eventsVaccine efficacyClinical malariaMalaria vaccineDouble-blindMalaria transmissionControl vaccineAsn-Ala-Asn-ProAge groupsStandard sitesMonths of follow-upAfrican childrenPerennial malaria transmissionBurden of malariaSeasonal malaria transmissionMalaria transmission intensityPhase 2b trialInjection site painFrequent adverse eventsCo-primary endpointsVaccine-induced antibodies
2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceThe impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussionFacteurs influençant l'observation de la deuxième et troisième dose pendant la chimioprévention du paludisme saisonnier (CPS) - Une étude quantitative au Burkina Faso, Mali et Niger
Somé A, Zongo I, Sagara I, Ibrahim A, Ahanhanzo C, Agbanouvi-Agassi E, Sayi D, Paré L, Kabré Z, Nikiéma F, Bazié T, Ouédraogo S, Sombié I, Dicko A, Adehossi E, Ouédraogo J, Dabiré K. Facteurs influençant l'observation de la deuxième et troisième dose pendant la chimioprévention du paludisme saisonnier (CPS) - Une étude quantitative au Burkina Faso, Mali et Niger. Revue D'Epidémiologie Et De Santé Publique 2023, 71: 101880. DOI: 10.1016/j.respe.2023.101880.Peer-Reviewed Original ResearchAltmetricSeasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R, Issiaka D, Zoungrana C, Sidibe Y, Tapily A, Nikièma F, Sompougdou F, Sanogo K, Kaya M, Yalcouye H, Dicko O, Diarra M, Diarra K, Thera I, Haro A, Sienou A, Traore S, Mahamar A, Dolo A, Kuepfer I, Snell P, Grant J, Webster J, Milligan P, Lee C, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases 2023, 24: 75-86. PMID: 37625434, DOI: 10.1016/s1473-3099(23)00368-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSeasonal malaria chemopreventionPhase 3 trialClinical malariaAlone groupMalaria Vaccine InitiativeMalaria chemopreventionSeasonal vaccinationProtective efficacyCombined groupPATH Malaria Vaccine InitiativeGlobal Health TrialsPrimary trial endpointSeasonal malaria transmissionSingle intervention groupSupplementary Materials sectionBougouni DistrictCause deathModified intentionProtocol populationControl vaccineMalaria vaccinationMalarial anemiaSevere malariaBlood transfusionHospital admissionWhy small-quantity lipid-based nutrient supplements should be integrated into comprehensive strategies to prevent child undernutrition in nutritionally vulnerable populations: response to Gupta et al.’s commentary
Dewey K, Stewart C, McDonald C, Wessells K, Arnold C, Prado E, Abbeddou S, Adu-Afarwuah S, Arnold B, Ashorn P, Ashorn U, Ashraf S, Becquey E, Black R, Brown K, Christian P, Colford J, Fernald L, Galasso E, Hallamaa L, Hess S, Humphrey J, Huybregts L, Iannotti L, Jannat K, Jimenez E, Lartey A, Le Port A, Leroy J, Luby S, Maleta K, Matchado A, Matias S, Mbuya M, Mridha M, Paul R, Okronipa H, Ouédraogo J, Pickering A, Prendergast A, Ruel M, Shaikh S, Weber A, Wolff P. Why small-quantity lipid-based nutrient supplements should be integrated into comprehensive strategies to prevent child undernutrition in nutritionally vulnerable populations: response to Gupta et al.’s commentary. World Nutrition 2023, 14: 79-85. DOI: 10.26596/wn.202314279-85.Peer-Reviewed Original ResearchEthical, regulatory and market related aspects of deploying Triple Artemisinin-Based Combination Therapies for malaria treatment in Africa
Bolarinwa O, Mokuolu O, Guissou R, Tou F, Ouedraogo J, Boon W, Moors E, Dhorda M, Amaratunga C, Cheah P, Tindana P, Haan F, Dondorp A. Ethical, regulatory and market related aspects of deploying Triple Artemisinin-Based Combination Therapies for malaria treatment in Africa. The Global Health Network Collections 2023 DOI: 10.21428/3d48c34a.4e367b81.Peer-Reviewed Original ResearchCitations